Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT ID: NCT06478212
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
42 participants
INTERVENTIONAL
2025-01-22
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1b: Vorasidenib and Temozolomide (TMZ)
Vorasidenib
To be taken by mouth once daily in 28-day cycles with no break between cycles
Temozolomide (TMZ)
To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Phase 2: Vorasidenib recommended combination dose (RCD) and Temozolomide (TMZ)
Vorasidenib
To be taken by mouth once daily in 28-day cycles with no break between cycles
Temozolomide (TMZ)
To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vorasidenib
To be taken by mouth once daily in 28-day cycles with no break between cycles
Temozolomide (TMZ)
To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have documented IDH1 or IDH2 mutation based on local testing of tumor tissue by an accredited laboratory
* Have adequate renal function, defined as a creatinine clearance ≥40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation: (140 - Age) × (Weight in kg) × (0.85 if female) / 72 × serum creatinine (mg/dL).
* Have adequate bone marrow function as evidenced by:
1. Absolute neutrophil count ≥1,500/mm3 or 1.5×109/L
2. Hemoglobin ≥9 g/dL or 90 g/L
3. Platelets ≥100,000/mm3 or 100×109/L
* Have expected survival of ≥3 months.
* KPS or LPPS ≥70 at the start of study treatment.
* Participants on corticosteroids for reasons related to glioma must be on a stable or decreasing dose (≤4mg/day dexamethasone or equivalent) for ≥5 days before the start of study treatment.
* Female participants of reproductive potential must have a negative serum pregnancy test before starting study treatment.
Phase 1b ONLY:
* Have histologically confirmed Grade 2, 3 or 4 IDHm (as per WHO 2021) glioma (astrocytoma or oligodendroglioma).
1. For oligodendroglioma: Have local testing at an accredited laboratory demonstrating presence of 1p19q co deletion
2. For astrocytoma: Have local testing by an accredited laboratory demonstrating lack of 1p19q co-deletion and/or documented loss of nuclear ATRX expression or ATRX mutation
* Are appropriate to receive TMZ as post-radiotherapy (RT) adjuvant therapy or as treatment for first disease recurrence after prior RT and/or chemotherapy, per Investigator judgement. For those receiving TMZ in the post-RT adjuvant setting, study treatment must begin no more than 6 weeks after completion of RT.
* Have adequate hepatic function as evidenced by:
1. Serum total bilirubin ≤1.5×upper limit of normal (ULN); if ≥1.5×ULN and due to Gilbert syndrome, total bilirubin ≤3×ULN with direct bilirubin ≤ULN,
2. AST and ALT ≤ULN, and
3. Alkaline phosphatase ≤2.5×ULN.
Phase 2 ONLY:
* Have histologically confirmed Grade 4 astrocytoma, IDHm (per 2021 WHO criteria). Those who meet the Grade 4 designation via homozygous deletion of CDKN2A/B are eligible.
* Have absence of 1p19q co-deletion (i.e., non-co-deleted, or intact) and/or documented loss of nuclear ATRX expression or ATRX mutation by local testing.
* Have received SOC RT with concurrent TMZ (RT-TMZ) before enrollment. Study treatment must begin no more than 6 weeks after completion of RT-TMZ.
* Have adequate hepatic function as evidenced by:
1. Serum total bilirubin ≤1.5×ULN; if ≥1.5×ULN and due to Gilbert syndrome, total bilirubin ≤3×ULN with direct bilirubin ≤ULN,
2. AST and ALT at or below the upper limit of normal. An elevation ≤1.5×ULN and considered not clinically significant by the Investigator may be allowed after Medical Monitor (Sponsor) approval, and
3. Alkaline phosphatase ≤2.5×ULN.
Exclusion Criteria
* Are pregnant or breastfeeding.
* Are participating in another interventional study at the same time; participation in non-interventional registries or epidemiological studies is allowed.
* Have leptomeningeal disease.
* Have a known coagulopathy.
* Received prior therapy with an IDH inhibitor, IDH-directed vaccine, or bevacizumab.
* Have a history of another concurrent primary cancer, with the exception of:
1. curatively resected non-melanoma skin cancer, or
2. curatively treated carcinoma in situ. Participants with other previously treated malignancies are eligible provided they have been disease-free for 3 years at Screening.
* Have a known diagnosis of replication repair-deficient glioma (e.g., a known diagnosis of constitutional mismatch repair deficiency or Lynch syndrome).
* Have a known hypersensitivity to any of the components or metabolites of vorasidenib or TMZ.
* Have significant active cardiac disease within 6 months before Screening, including New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke.
* Have heart rate corrected QT interval (using Fridericia's formula) (QTcF) ≥450 msec or have other factors that increase risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome). Right bundle branch block and prolonged QTcF interval may be permitted based on local cardiology assessment.
* Have known active hepatitis B (HBV) or hepatitis C (HCV) infections, known positive human immunodeficiency virus (HIV) antibody results, or acquired immunodeficiency syndrome (AIDS) related illness. Participants with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted. Participants with chronic HBV or HIV that is adequately suppressed per institutional practice will be permitted.
Phase 1b ONLY:
* For those receiving TMZ in the frontline post-RT adjuvant setting: Have progressive disease during RT or after completion of SOC RT and before the start of study treatment.
* For those receiving TMZ in the recurrent disease setting:
1. Have received prior systemic anti-cancer therapy (other than surgery) within 1 month (or 6 weeks for nitrosoureas and 6 months for TMZ) of the start of study treatment. In addition, the first dose of study treatment should not occur before a period of 28 days or ≥5 half-lives of any prior investigational agent have elapsed, whichever is longer.
2. Have received more than one prior line of therapy for glioma (Note: prior RT + chemotherapy is considered one line of therapy).
* Had Grade ≥2 hepatic-related toxicity (AST, ALT, and/or bilirubin elevations) during prior systemic chemotherapy
* Had Grade 4 hematologic toxicity (excluding lymphopenia) that did not recover within 7 days during a prior course of TMZ
Phase 2 ONLY:
* Have received any other glioma-directed therapy other than surgery and SOC RT-TMZ
* Have progressive disease during RT-TMZ or after completion of SOC RT-TMZ and before the start of study treatment.
* Had Grade 4 hematologic toxicity (excluding lymphopenia) that did not recover within 7 days during concurrent RT-TMZ
* Had Grade ≥2 hepatic-related toxicity (AST, ALT, and/or bilirubin elevations) during concurrent RT-TMZ
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Recherches Internationales Servier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Los Angeles
Los Angeles, California, United States
University of California, San Francisco (UCSF) School of Medicine
San Francisco, California, United States
University of Miami
Miami, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
MD Anderson Cancer Center
Houston, Texas, United States
Medical University of Vienna - AKH
Vienna, , Austria
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, , China
Huashan Hospital, Fudan University
Shanghai, , China
Hôpital Pierre Wertheimer
Lyon, , France
Hôpital Pitié-Salpêtrière
Paris, , France
IUCT-Oncopole Institut Universitaire du Cancer
Toulouse, , France
Universitätsklinikum Heidelberg
Heidelberg, , Germany
Medizinische Fakultät Mannheim, Universität Heidelberg
Mannheim, , Germany
Universitätsklinikum Regensburg
Regensburg, , Germany
Rabin Medical Center - Davidoff Cancer Center
Petah Tikva, , Israel
The Tel Aviv Sourasky Medical Center (TASMC) (Ichilov Hospital)
Tel Aviv, , Israel
Instituto Clinico Humanitas IRCCS
Rozzano, Milan, Italy
IOV - Ospedale Busonera
Padua, , Italy
Ospedale Molinette - Centro Oncologico Ematologico
Turin, , Italy
Kumamoto University Hospital
Kumamoto, , Japan
Kyoto University Hospital
Kyoto, , Japan
Nagoya University Hospital
Nagoya, , Japan
National Cancer Center Hospital
Tokyo, , Japan
Erasmus MC
Rotterdam, , Netherlands
H. Valle de Hebron
Barcelona, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Christie Hospital
Manchester, , United Kingdom
The Royal Marsden in Sutton
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Institut de Recherches Internationales Servier (I.R.I.S.) Clinical Studies Department
Role: CONTACT
Phone: +33 1 55 72 60 00
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S095032-211
Identifier Type: -
Identifier Source: org_study_id